MedTrace Logo

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

NCT00083694 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2010-07-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.

Conditions

Interventions

DRUG

Thalidomide

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Barthel Barlogie, M.D., Ph.D. · UAMS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083694 on ClinicalTrials.gov